The ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine, for size and size distribution, and atomic force microscopy (AFM) was used for the determination of morphological properties. By both differential scanning calorimetry (DSC) and X-ray diffractometry, crystalline behaviour of lipids and drug was assessed.
Introduction
Edelfosine (ET-18-OCH 3 , 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine) is the prototype of a promising class of antitumor agents, collectively known as alkyl-lysophospholipid analogues (ALPs) or antitumor ether lipids, that do not target the DNA, but affect the cell membrane and the apoptotic machinery of the cancer cell [1] . Phase I studies have shown a good tolerability of the drug but with haematological and systemic side effects [1, 2] . However, although edelfosine has been shown to exert potent antineoplastic effects in vitro [3, 4] , the antitumor activity in phase II clinical studies has been only moderate [5] . Moreover, ALPs show manifold biological effects in addition to their antineoplastic actions, including an antiparasitic effect on Leishmania [6] as well as an inhibition of the cell membrane phospholipid turnover [7] and a potent inhibition of neovascularization [8] , protein kinase C and Na + /K + -ATPase [9] .
Edelfosine has also been given intravenously, but this provoked haemolysis as a major side effect [10] . This led to the only formulation developed so far, the TLC ELL-12, in which edelfosine was included into liposomes [11] to avoid the haemolytic toxicity of the drug. However, the main inconvenience of liposomes is their rapid clearance from plasma in comparison with other delivery systems.
Lipid nanoparticles have been proposed as an alternative for the existing traditional particulate systems, such as previously mentioned liposomes or polymeric nanoparticles. These particulate systems made from solid lipids started being developed in the early nineties. They provide physical stability, controlled release and a wide variety of application routes (parenteral, oral, dermal, ocular, pulmonary and rectal) [12] [13] [14] [15] [16] .
Lipid nanoparticles are basically composed of a high melting point lipid that acts as a solid core, covered by surfactants. Lipids used to form these matrices are biodegradable raw materials that are physiologically tolerated [17] : triglycerides (i.e. tristearin), partial glycerides (i.e. Compritol), fatty acids (i.e. stearic acid), steroids (i.e. cholesterol) or waxes (i.e. cetyl palmitate) [18] .
The formulation methods are also diverse. Emulsion formation and solvent evaporation method has been widely used for particle formation, although other methods like high pressure homogenization [18] , solvent diffusion methods in aqueous solutions [19] or hot emulsion methods [18, 20] have also been employed. Drawbacks associated to this kind of formulations, like limited drug loading capacity, adjustment of drug release profile and potential drug expulsion during storage have been reported [21] . Besides, drug loading capacity is limited by the solubility of the drug in the lipid melt, the structure of the lipid matrix and the polymorphic state of the lipid matrix.
Comparing with the previously mentioned liposomes, the main improvement of the lipid nanoparticles is their physical and chemical long-term stability up to 12 -24 months [13] , even though an increase in particle size has been reported in a lesser time [22] . As a feasible solution for this setback, the freeze-drying process has shown to increase physicochemical stability of lipid particles over large periods of time [23] .
Taking into account this information, the aim of this study was to develop a new formulation which would provide a controlled release for the antitumor lipid edelfosine, in order to improve its therapeutic activity.
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Materials and Methods

Materials
Edelfosine was from INKEYSA (Barcelona, Spain 
Preparation of lipid nanoparticles
Encapsulation efficiency
Edelfosine was extracted by dissolving 10 mg of nanoparticles in 1 ml of chloroform and then mixed with 3 ml of ultra pure water. The mixture was vortexed for 1 minute and then centrifuged at 9500 g for 10 minutes. The supernatant was analysed by a HPLC-MS method, which is a slight modification of a previously developed method [24] . The apparatus used for the HPLC analysis was a Model 1100 series LC coupled 
Particle size, size distribution and zeta potential
Particle size and distribution of the nanoparticles were measured by photon correlation spectroscopy (PCS) using a Zetasizer Nano (Malvern Instruments, UK).
Each sample was diluted with distilled water until the appropriate concentration of particles was achieved to avoid multiscattering events. The obtained homogenous suspension was examined to determine the volume mean diameter, size distribution and polydispersity.
The electrophoretic mobility and zeta potential were determined by Laser Doppler Velocimetry using a Zetasizer Nano (Malvern Instruments, UK).
Morphology
Atomic force microscopy (Cervantes AFM System, Nanotec Electrónica, S.L., Spain) was employed to determine the shape and surface morphology of the nanoparticles. AFM was conducted with Nanoscope IIa IIIa in the tapping mode. The nanoparticle sample was mounted on a metal stab and scanned by the AFM maintained in a constant temperature and vibration time environment.
Thermal analysis of freeze-dried lipid nanoparticles
The thermal characteristics of selected batches of nanoparticles were determined by differential scanning calorimetry thermal analysis using a 2920 DSC (Universal V3.6C
TA Instruments, USA). The scan rate was 10 ºC/min in the temperature range from -10 ºC to 275 ºC and a N 2 flow of 20 L/min. An empty pan was used as reference standard.
Indium (purity ≥99.95 %, Fluka, Switzerland) was employed to check the calibration of the calorimetric system.
X-ray studies of freeze-dried lipid nanoparticles
X-ray diffraction measurements were performed in order to clearly elucidate the solid state of both lipids and drug in lipid nanoparticles, using a Bruker D8 Advance Xray diffractometer (Bruker Biosciences Española, S.A., Spain). The X-ray diffractogram was scanned with the diffraction angle increasing from 2° to 40°, 2θ angle, with a step angle of 0.02° and a count time of 1 s at a constant temperature of 25 ºC.
In vitro release studies
The release rate of edelfosine from lipid nanoparticles was measured in PBS medium (pH 7. 
Results and discussion
Particle size, size distribution and zeta potential
Structurally, edefosine has a structure of an amphifile, with a part of the molecule exhibiting hydrophobicity and another part exhibiting hydrophilicity, like a surfaceactive agent (Fig.1) .
Edelfosine-loaded lipid nanoparticles were obtained by either simple or multiple emulsion solvent evaporation method, and freeze-dried. These nanoparticles were then characterized to assess the effect of the different lipids and surfactant concentrations on mean particle size, size distribution and surface charge.
Using lipids as matrices for the particles, different characteristics can be obtained by optimizing the formulation parameters such as type of lipids, surfactants, organic solvents and emulsifying procedure chosen [18] . The presence of an anionic surfactant is important to reduce the dynamic interfacial tension and to stabilize the nanosuspension. The surfactant is adsorbed on the nanoparticle surface, increasing the steric repulsion between particles. In this study, Tween ® 80 was tested at two different concentrations (w/v), being sufficient to obtain small lipid nanoparticles and permitting the removal of its excess by centrifugation and washing.
The average size and polydispersity indices of lipid nanoparticles formulated with different lipids are reported in Table 1 Zeta potential can make a prediction about the stability of colloid dispersions. A high zeta potential (> 30 mV) can provide an electric repulsion to avoid the aggregation of particles [25] . The incorporation of edelfosine into lipid nanoparticles had no significant influence on the zeta potentials of particles, which was negative in all cases.
However, as the concentration of surfactant was increased in the formulation the zeta potential was found to be more negative (Table 1 ). This could be due to the adsorption of the surfactant on the particle surface, forming a denser surfactant film, thus eliciting a reduced electrophoretic mobility.
Drug entrapment efficiency and loading capacity
Over the past few years many different drugs had been successfully incorporated in lipid nano-or microparticles [20, [26] [27] [28] . Relatively higher drug encapsulation efficiency was one of the major advantages of lipid nanoparticles. It is also known that the lipid crystalline structure related to the chemical nature of the lipid is a key factor to determine whether a drug will be expelled or firmly incorporated into the carrier systems. In the nanoparticle structure, the lipid forming highly crystalline state with a perfect lattice would lead to drug expulsion. On the other hand, imperfections (lattice defects) of the lipid structure could offer space to accommodate the drugs [29] . As a result, the structure of less ordered arrangement in the nanoparticles would be beneficial to the drug loading capacity like the samples in this study.
From the results listed in Table 2 , it can be observed that the entrapment efficiency of edelfosine in the lipid nanoparticles prepared by the simple emulsion solvent evaporation method ranged from about 4 to 10 % for stearic acid nanoparticles. On the other hand, nanoparticles formulated using Compritol ® encapsulated more than 80 % of the drug (Table 2 ). This high encapsulation efficiency in comparison to the stearic acid nanoparticles is likely to be due to the partially amorphous state of the Compritol ® in the formulation, which allows more edelfosine to be incorporated among lipid chains. It can also be observed that the emulsifier concentrations investigated in this study (0.5 % and 1 % Tween 80) do not affect the encapsulation efficiency.
On the other hand, lipid nanoparticles prepared by the multiple emulsion solvent evaporation method showed very low encapsulation efficiency, less than 1 % (data not shown).
Morphology
In order to investigate the shape and surface morphology of the Compritol ® nanoparticles, atomic force microscopy was employed. The AFM images reveal the fine structure of the Compritol ® lipid nanoparticle surface ( Fig. 2A) . They give clear 3D morphological images of spherical nanoparticles of sub-400 nm diameter and they also confirm that there was no aggregation or adhesion among the nanoparticles (Fig. 2C) .
Furthermore, the surface morphology of the nanoparticles could be seen closely from the AFM images. It was noticeable from the zoom-in picture (Fig. 2B ) the smooth surface morphology of the nanoparticles.
DSC and X-ray diffractometry assays
Lipid nanoparticles were analysed by DSC and X-ray diffractometry to investigate the crystal pattern of both edelfosine and lipids, because this aspect could influence the in vitro and in vivo release of the drug from the systems. Unloaded stearic acid nanoparticles (Fig. 4A) show two sharp peaks corresponding to those of the stearic acid, whereas the diffraction pattern of Compritol ® (Fig. 4B) showed a typical double peak that is significantly modified when formulated into nanoparticles.
Comparing these results with edelfosine loaded lipid nanoparticles, some crystalline drug signal could still be detected, indicating a possible coexistence of edelfosine in both crystalline and amorphous states, being this last one the predominant. As a result, edelfosine would enrich the particle surface when formulated with stearic acid, whereas it would be incorporated among the lipid chains of Compritol ® .
In vitro release studies
The amount of edelfosine released from lipid nanoparticles was determined by an in vitro release assay, in an effort to assess whether edelfosine-incorporating lipid nanoparticles might be useful as a sustained-release dosage form. (Fig.5) . Conversely, the initial release burst for nanoparticles prepared using Compritol ® was less than 40 % within the first 20 minutes. The reason for the high initial release of edelfosine from the stearic acid nanoparticles could be the diffusion release of edelfosine distributed near the surface and in the outer portion of the nanoparticles [12] . These results were in accordance with the observations made by DSC and X-ray diffractometry.
Afterwards, the release rate slowed for both formulations, reaching 55 % after 24 h for nanoparticles prepared with Compritol ® , and 98 % for the stearic acid nanoparticles.
The release of a drug from the dosage form implies a crucial step, which is the dissolution of the drug. This process is ruled by a release rate constant (k d ) that can be easily estimated and it is different depending, among other factors, on the composition of the particle. In our study, this constant was estimated for the release of edelfosine from lipid nanoparticles formulated either with stearic acid or Compritol ® .
Results showed that there is a different release profile depending on the lipid. 
Conclusions
The present research paper proposed a novel formulation for edelfosine by using lipid nanoparticles. It can be concluded that Compritol ® presents advantages as a matrix material for the manufacture of the nanoparticles and the controlled release of edelfosine.
Current studies are aimed at evaluating the in vitro (in cell lines) and in vivo efficacy of these newly developed formulations.
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